Results 71 to 80 of about 3,056 (181)

Neurocardiology: Brain–Heart Interactions in the Heart

MedComm, Volume 7, Issue 9, September 2026.
The heart and brain maintain systemic homeostasis through bidirectional communication involving neural, biochemical, and mechanical pathways. Dysregulation of these pathways contributes to a spectrum of conditions involving heart–brain interactions, including Takotsubo syndrome, the epileptic heart, stroke–heart syndrome, heart failure, cardiac ...
Wentao Wang, Hao Jia, Han Han, Jiangping Song   +3 more
wiley   +1 more source

Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Alzheimer's disease affects tens of millions of people worldwide and is associated with the self‐assembly of the Aβ42 peptide into amyloid aggregates. Among the species formed during this process, soluble oligomeric intermediates are the most closely linked to neurotoxicity and are therefore an attractive target for both therapeutic and ...
Magdalena Nowinska, Elijah Suh, Casey Mogilevsky, Michele Vendruscolo   +3 more
wiley   +1 more source

Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels

Aging Cell, Volume 25, Issue 9, September 2026.
The identification of the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) challenges the century‐old “immune‐privileged” dogma of the central nervous system (CNS), establishing a critical mechanistic link between impaired waste clearance (Aβ/tau) and the pathogenesis of Alzheimer's disease (AD).
Bingbing Song, Wei Wang, Siqi Liu, Xi Jin, Yan Qi, Mingquan Li, Dongjie Yue, Yu Liu, Xiangqi Li, Lei Yin, Lina Feng   +10 more
wiley   +1 more source

Alzheimer’s Disease in the Context of an Aging Society: Challenges and Future Directions

Journal of Education, Health and Sport
Alzheimer’s disease (AD) remains the most prevalent form of dementia and a pressing public health concern, particularly in the context of global population aging.
Aleksandra Boral, Bartłomiej Czarnecki, Wiktoria Pniok, Julia Koczur, Wiktor Werenkowicz, Dominika Kryś, Joanna Brzoza, Michał Górski, Wojciech Kurkiewicz   +8 more
doaj   +1 more source

Brain pathology in relation to somatic diseases: Exploring the body–brain crosstalk

Journal of Internal Medicine, Volume 300, Issue 3, Page 223-237, September 2026.
Abstract Several somatic diseases have been consistently linked with an increased dementia risk. However, the underlying neuropathological substrates remain poorly characterized. This narrative review aims to summarize evidence on the association between common age‐related somatic conditions (i.e., heart diseases, type 2 diabetes, kidney disease, liver
G. Grande, M. Valletta, F. Gasparini, D. L. Vetrano, M. Canevelli, J. R. Bacci, C. Qiu, A. Marengoni, M. Toccaceli Blasi, H. Xu, L. Fratiglioni, M. M. Mielke   +11 more
wiley   +1 more source

Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer’s disease: a systematic review and network meta-analysis

Frontiers in Neuroscience
BackgroundThe management of Alzheimer’s disease has shifted toward disease-modifying therapies aimed at delaying disease progression rather than focusing solely on symptomatic treatment.
Shiyu Liu, Shiyu Liu, Min Zhao, Min Zhao, Yuan Liu, Yuan Liu, Xin Yang, Xin Yang, Huayu Yan, Huayu Yan, Hongcai Xu, Hongcai Xu, Yabo Wu, Yabo Wu, Yumin Xu, Yumin Xu   +15 more
doaj   +1 more source

Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study

Psychiatry and Clinical Neurosciences, Volume 80, Issue 9, Page 740-747, September 2026.
Aim To determine the smallest worthwhile difference (SWD) for lecanemab, a disease‐modifying drug for Alzheimer's disease (AD), among the general Japanese population using a benefit‐harm trade‐off method. Methods We conducted an online survey with 658 participants to evaluate their preferences for the treatment effect of lecanemab, given its associated
Aran Tajika, Kenji Omae, Ethan Sahker, Yan Luo, Yoshiteru Takekita, Toshi A. Furukawa   +5 more
wiley   +1 more source

“Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head‐to‐head comparative data are absent.
Eric Dinnerstein
doaj   +1 more source

Pharmacological Management of Mild Cognitive Impairment: From Symptomatic Treatment to Disease Modification—A Narrative Review

NeuroSci
Mild cognitive impairment (MCI) is a nosological entity that requires special attention from a therapeutic perspective, because annual conversion rates to dementia of 5–15% in these cases are considered typical.
Andrei Gabriel Mangalagiu, Bogdan Mircea Petrescu, Sorin Riga, Octavian Vasiliu   +3 more
doaj   +1 more source

A comparison of the effectiveness and safety between the antibodies Donanemab and Lecanemab in early Alzheimer's disease

Introduktion: Alzheimers sjukdom (AD) är den vanligaste formen av demens. Antalet individer med demensdiagnos förväntas öka från cirka 57 miljoner år 2019 till 152,8 miljoner år 2050.
Rehnman, Sanna
core   +2 more sources